​Antibody Drug Conjugates in Cancer Drug Development
White Paper

Antibody-drug conjugates (ADCs), which now account for approximately 20% of the clinical pipeline of antibodies for cancer, are comprised of three components: a monoclonal antibody chosen to target a specific receptor, a potent cytotoxic agent, and a linker that connects (conjugates) the antibody to the cytotoxin. From an efficacy perspective, there is substantial diversity of the drugs, linkers and drug-to-antibody ratios of the ADCs under development. From a safety perspective, the mechanisms of toxic effects are complex, with contributions from all three components of the conjugate. Successfully developing and obtaining regulatory approval for ADCs is therefore a challenging process. This White Paper discusses the role of real-world data to generate evidence that enables development decisions to be made earlier and more efficiently.

You may also be interested in
Contact Us
Contact Us
Contact Us

Email Us

Get in touch today to discover the right solutions for you.

Call Us

We are pleased to speak with you during our standard business hours.

U.S. Toll-Free only
+1 866 267 4479

For international call please find a number in our toll-free list.